Health Canada on Friday suspended distribution of the Johnson & Johnson vaccine due to concerns over product quality and safety.
• Read also: WHO issues emergency clearance for Moderna COVID-19 vaccine
The move affected more than 300,000 doses of Johnson & Johnson vaccine shipped to Canada on Wednesday.
“Health Canada has learned that a drug produced by Emergent has been used to produce doses of Janssen vaccine that were originally intended to be used in Canada and were received on April 28,” it said. a press release clarifying that the substance is part of additional processing to convert the product into a vaccine.
“Like all vaccines imported into Canada, Janssen vaccines can only be distributed if Health Canada is satisfied that they meet the Department’s high standards for quality, safety and efficacy,” he said.
Health Canada has also confirmed that it continues to work with Janssen (Johnson & Johnson), AstraZeneca and the United States Food and Drug Administration (FDA) to ensure the Emerging BioSolutions facility in Baltimore, Maryland meets manufacturing standards. …
This is not the first time this factory has come under the spotlight over COVID-19 vaccinations after it raised concerns about quality control of its products nearly a year ago.
The ministry then gave assurances that all vaccines, including the AstraZeneca vaccine, were compliant.
“Health Canada remains confident that the 1.5 million doses of AstraZeneca vaccine imported into Canada from this facility meet the requirements,” he added.